Knight Therapeutics SMA 50
What is the SMA 50 of Knight Therapeutics?
The SMA 50 of Knight Therapeutics, Inc. is CAD$6 +5.47%
What is the definition of SMA 50?
SMA 50 is an average stock price from the last 50 days calculated as an unweighted mean of the previous 50 stock closing prices.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 of companies in the Health Care sector on TSX compared to Knight Therapeutics
What does Knight Therapeutics do?
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Companies with sma 50 similar to Knight Therapeutics
- CES Solutions has SMA 50 of $6 -6.77%
- A2Z Technologies Canada has SMA 50 of $6 +47.86%
- Sterling Bancorp Inc has SMA 50 of $6 +1.55%
- Capricorn Metals Ltd has SMA 50 of AUD$6 +0.52%
- Nomura has SMA 50 of $6 -5.02%
- China International Marine Containers () Co has SMA 50 of HKD$6 -16.02%
- Knight Therapeutics has SMA 50 of CAD$6 +5.47%
- Hanesbrands has SMA 50 of $6 +7.49%
- G1 Therapeutics Inc has SMA 50 of $6 +20.58%
- AEGON NV has SMA 50 of €6 -5.20%
- Nuveen Credit Strategies Income Fund has SMA 50 of $6 +4.12%
- BP Plc has SMA 50 of $6 -8.60%
- Riskified has SMA 50 of $6 -23.79%